ISSAR has developed a novel synthetic peptide therapeutically targeting joints, which is currently under preclinical trials. We are hoping to improve the quality of life for patients suffering with Rheumatoid arthritis in the near future.
The WHO and UN have recognized four major musculoskeletal conditions contributing to a major burden on individuals and health care systems across the world. These include osteoarthritis, rheumatoid arthritis, osteoporosis and lower back pain.
These conditions result in chronic pain and long-lasting physical disability in the affected population. The prevalence and incidence of these conditions increases with age, lifestyle and other physical aspects.
ISSAR has developed a novel peptide drug for angiogenesis related diseases and inflammatory disorders. This novel peptide drug designated as IS-181 targets the VEGFR-2 which is the major receptor for angiogenesis function.
IS-181 causes modulation of VEGFR-2 receptors which are the major receptors for angiogenesis function, through down-regulation of MAPK/ p38/ ERK1/2 pathways.